SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-21-008273
Filing Date
2021-12-02
Accepted
2021-12-02 07:17:04
Documents
15
Period of Report
2021-12-02
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_120221.htm   iXBRL 8-K 15348
2 PRESS RELEASE exh_991.htm EX-99.1 14175
3 exh991small_1.jpg GRAPHIC 3298
  Complete submission text file 0001171843-21-008273.txt   239948

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3069
5 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25640
6 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
7 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
8 EXTRACTED XBRL INSTANCE DOCUMENT f8k_120221_htm.xml XML 3126
Mailing Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5
Business Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5 450-686-4555
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 211464947
SIC: 2834 Pharmaceutical Preparations